(E)-N-ethylbut-2-enamide | 14064-76-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-N-ethylbut-2-enamide
• 英文别名: N-Ethyl-crotonamid；N-ethylcro-tonamide
• CAS: 14064-76-7
• 化学式: C₆H₁₁NO
• 分子量: 113.159
• InChiKey: ILZUEDQCWIOLLZ-HWKANZROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-N-ethylbut-2-enamide 在 iron(III) chloride 、 S-1,1'-联-2-萘酚 、 间氯过氧苯甲酸 、 三苯基氧化膦 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 46.0h， 生成 (4S,5S)-2,3-acetonide-ethylbutyramide
  参考文献：
  名称：

  METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE

  摘要：

  揭示了一种合成盐酸氢七氢生物蝶啶的方法。本公开减少了盐酸氢七氢生物蝶啶的合成路径，采用不对称合成方式在一个含有钐催化剂的四氢呋喃溶液中引入手性中心作为催化剂，并通过选择性催化获得具有高对映异构体值的目标化合物。产率提高，原料廉价且易得，成本显著降低，从而为盐酸氢七氢生物蝶啶的大规模工业生产提供了有效的方案。

  公开号：

  US20150105555A1
• 作为产物：
  描述：

  (E)-巴豆氯 、 乙胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 以98%的产率得到(E)-N-ethylbut-2-enamide
  参考文献：
  名称：

  Identification and optimization of piperine analogues as neuroprotective agents for the treatment of Parkinson’s disease via the activation of Nrf2/keap1 pathway

  摘要：

  Parkinson's disease (PD) is a slowly progressive and complex neurodegenerative disorder. Up to date, there are no approved drugs that could slow or reverse the neurodegenerative process of PD. Here, we reported the synthesis of series of piperine analogues and the evaluation of their neuroprotective effects against hydrogen peroxide (H2O2) induced damage in the neuron-like PC12 cells. Among these analogues, 3b exhibited the most potent protection effect and its underlying mechanism was further investigated. Further results indicated that the ROS scavenging and cytoprotection effect of 3b might be related to the Nrf2 activation and upregulation of related phase II antioxidant enzymes, such as HO-1 and NQO1. In in vivo study, oral administration (100 mg/kg) of 3b significantly attenuated PD-associated behavioral deficits in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD and protected tyrosine hydroxylase-immunopositive dopaminergic neurons. Our results provided evidence that 3b might be a promising candidate for Parkinson's disease treatment. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112385

文献信息

• [EN] MK2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS MK2 ET UTILISATIONS ASSOCIÉES
  申请人：CELGENE AVILOMICS RES INC

  公开号：WO2014149164A1

  公开（公告）日：2014-09-25

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• PROCESS FOR ALKENYLATING CARBOXAMIDES
  申请人：Staffel Wolfgang

  公开号：US20090131657A1

  公开（公告）日：2009-05-21

  The present invention relates to a process for preparing N-(1-alkenyl)carboxamides of the formula I, which comprises reacting a carboxamide of the formula II with an alkyne of the formula III in the presence of a catalyst selected from among carbonyl complexes, halides and oxides of rhenium, manganese, tungsten, molybdenum, chromium and iron.

  本发明涉及一种制备式I的N-(1-烯基)羧酰胺的方法，包括在选择自铼、锰、钨、钼、铬和铁的羰基配合物、卤化物和氧化物之一作为催化剂的情况下，将式II的羧酰胺与式III的炔烃反应。
• ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS
  申请人：Singh Juswinder

  公开号：US20100185419A1

  公开（公告）日：2010-07-22

  The invention is an algorithm and method for designing an inhibitor that covalently binds a target polypeptide. The algorithm and method can be used to rapidly and efficiently convert reversible inhibitors into irreversible inhibitors.

  这项发明是一种用于设计与靶多肽共价结合的抑制剂的算法和方法。该算法和方法可用于快速高效地将可逆抑制剂转化为不可逆抑制剂。
• [EN] HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES ET LEURS UTILISATIONS
  申请人：AVILA THERAPEUTICS INC

  公开号：WO2009051822A1

  公开（公告）日：2009-04-23

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物、药学上可接受的组合物以及使用它们的方法。
• Protein Kinase Conjugates and Inhibitors
  申请人：Celgene Avilomics Research, Inc.

  公开号：US20170174691A1

  公开（公告）日：2017-06-22

  The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.

  该发明涉及含有蛋白激酶的蛋白共轭物，该蛋白激酶在ATP结合位点含有半胱氨酸残基，并且与该半胱氨酸残基共价且不可逆地结合的抑制剂，从而不可逆地抑制了蛋白激酶的活性。该发明还涉及不可逆地抑制蛋白激酶的化合物。